CME Information

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Discuss strategies to effectively identify side effects, optimize therapy, and improve outcomes for patients with PAH
• Review the evidence for initiating combination therapy in patients with PAH
• Assess PAH risk accurately

ACTIVITY FACULTY
Steven Nathan, MD
Medical Director, Advanced Lung Disease & Lung Transplant Program
Inova Fairfax Hospital

Christopher King, MD
Medical Director, Transplant and Advanced Lung Disease Critical Care Program
Inova Fairfax Hospital

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity
4. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
5. Credit documentation/reporting:
   • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

ACCREDITED PROVIDER
This activity is provided by The France Foundation.

TARGET AUDIENCE
This activity is intended for pulmonologists and cardiologists.

STATEMENT OF NEED
Pulmonary arterial hypertension (PAH) is a progressive, irreversible disease that is frequently delayed in diagnosis and treatment. Treatment is critical to reduce risk of progression. Clinicians, however, are ill-prepared to make rapid diagnosis of PAH and choose optimal therapies to manage these patients on an individualized, targeted basis. Given the challenges associated with timely diagnosis and treatment of PAH, continuing education for clinicians managing this disease is critical.

ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures
The faculty listed below report that they have relevant financial relationships to disclose:

• Christopher King, MD, FACP, FCCP, reports that he has done consulting for Actelion, Boehringer Ingelheim Pharmaceuticals, Inc, and Genentech. He has also served on a speakers bureau for Actelion, Boehringer Ingelheim Pharmaceuticals, Inc, and United Therapeutics.
• Steven Nathan, MD, FCCP, reports that he has done consulting for Bellerophon, Boehringer Ingelheim Pharmaceuticals, Inc, Galapagos, United Therapeutics, and Roche-Genetech. He has served on a speakers bureau for Boehringer Ingelheim Pharmaceuticals, Inc and Roche-Genentech. He has also participated in contract research for Bellerophon and United Therapeutics.

DISCLOSURE OF UNLABELED USE
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.